Summary & Overview
HCPCS C9301: Obecabtagene Autoleucel, CD19 CAR T-cell Therapy
HCPCS Level II code C9301 designates a single therapeutic dose of Obecabtagene autoleucel — a CD19-directed CAR T-cell therapy — and explicitly includes leukapheresis and dose preparation procedures. As a high-cost, specialized cellular therapy, this code is central to billing for complex oncology treatments delivered in settings equipped for cell collection, manipulation, and infusion. Its proper use affects claims processing, reimbursement pathways, and provider reporting for advanced therapies nationwide.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical scope and administrative footprint, benchmarks for payer coverage practices, common billing modifiers, and the typical sites of service where such therapies are provided. The publication also outlines policy considerations relevant to public and commercial payers, coding nuances for single-dose cellular products, and the administrative components that commonly accompany CAR T-cell therapy claims.
This summary equips coding professionals, revenue-cycle staff, and policy analysts with the context needed to interpret C9301 in national billing and coverage discussions, and points to areas where payer policies and documentation requirements commonly influence claim adjudication.
Billing Code Overview
HCPCS Level II code C9301 represents Obecabtagene autoleucel, up to 400 million CD19 CAR-positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose. This code covers a single therapeutic dose of a CD19-directed CAR T-cell therapy product, and the listed description includes both the cellular product and associated leukapheresis and dose preparation services.
-
Service type: Cellular gene therapy product administration and preparation
-
Typical site of service: Hospital outpatient infusion or specialty infusion center capable of leukapheresis and cellular therapy handling
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with relapsed or refractory CD19-positive B‑cell malignancy (for example diffuse large B‑cell lymphoma) who has failed prior lines of systemic therapy and meets eligibility for autologous CAR T‑cell therapy. The care pathway begins with a multidisciplinary hematology/oncology assessment, confirmation of CD19 antigen expression on tumor cells, and preauthorization with the patient’s payer. The patient undergoes leukapheresis as an outpatient procedure to collect peripheral blood mononuclear cells, which are shipped to a manufacturing facility for ex vivo genetic modification to produce obecabtagene autoleucel and expanded to a dose up to 400 million CD19 CAR‑positive viable T cells. While manufacturing occurs (typically 2–4 weeks), the patient may receive bridging therapy as needed and undergo baseline organ function testing, infectious disease screening, and counseling on risks including cytokine release syndrome and neurotoxicity.
On the day of infusion, the patient usually receives lymphodepleting chemotherapy (commonly fludarabine and cyclophosphamide) administered inpatient or in an outpatient infusion center depending on institutional protocol. The therapeutic dose defined by C9301 includes leukapheresis and dose preparation procedures; the infusion of the CAR T product is performed under close monitoring with immediate access to critical care support. Post‑infusion monitoring occurs in an inpatient or specialized outpatient setting for at least several days to weeks with serial labs, neurologic checks, and treatment protocols for cytokine release syndrome (e.g., tocilizumab) and immune effector cell‑associated neurotoxicity syndrome. Follow‑up includes ongoing assessments for response, infectious complications, and long‑term survivorship care.
Typical sites of service: inpatient hospital, specialized outpatient infusion center, or ambulatory apheresis unit. Service type: cell therapy product administration and associated collection/manufacturing preparation steps included with the billed HCPCS C9301.